open access

Vol 12, No 5 (2017)
Case Reports
Published online: 2017-11-22
Get Citation

Peripartum cardiomyopathy — case report

Anna Maria Bednarek, Marcin Wita, Maciej Wybraniec, Katarzyna Mizia-Stec
DOI: 10.5603/FC.2017.0092
·
Folia Cardiologica 2017;12(5):489-492.

open access

Vol 12, No 5 (2017)
Case Reports
Published online: 2017-11-22

Abstract

Peripartum cardiomyopathy (PPCM) is fast extending cardiomyopathy, which is manifested by heart failure in the last month of pregnancy or within 5 months after childbirth. Mortality described in various publications ranges from 7 to 50%. The article describes fast process of PPCM in 25-year-old woman with cardiogenic shock in the initial period, and then a gradual improvement, which requires diagnostic and therapeutic steps.

Abstract

Peripartum cardiomyopathy (PPCM) is fast extending cardiomyopathy, which is manifested by heart failure in the last month of pregnancy or within 5 months after childbirth. Mortality described in various publications ranges from 7 to 50%. The article describes fast process of PPCM in 25-year-old woman with cardiogenic shock in the initial period, and then a gradual improvement, which requires diagnostic and therapeutic steps.
Get Citation

Keywords

Peripartum cardiomiopathy; acute circulatory failure; levosimendan

About this article
Title

Peripartum cardiomyopathy — case report

Journal

Folia Cardiologica

Issue

Vol 12, No 5 (2017)

Pages

489-492

Published online

2017-11-22

DOI

10.5603/FC.2017.0092

Bibliographic record

Folia Cardiologica 2017;12(5):489-492.

Keywords

Peripartum cardiomiopathy
acute circulatory failure
levosimendan

Authors

Anna Maria Bednarek
Marcin Wita
Maciej Wybraniec
Katarzyna Mizia-Stec

References (6)
  1. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation. 2005; 111(16): 2050–2055.
  2. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008; 29(2): 270–276.
  3. Desplantie O, Tremblay-Gravel M, Avram R, et al. BRO-HF Initiative Investigators. The medical treatment of new-onset peripartum cardiomyopathy: a systematic review of prospective studies. Can J Cardiol. 2015; 31(12): 1421–1426.
  4. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016; 18(9): 1096–1105.
  5. Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation. 1971; 44(6): 1053–1061.
  6. Biteker M, Duran NE, Kaya H, et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin Res Cardiol. 2011; 100(7): 571–577.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl